<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630666</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2017-13</org_study_id>
    <nct_id>NCT03630666</nct_id>
  </id_info>
  <brief_title>Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients</brief_title>
  <acronym>OLIGOPELVIS2</acronym>
  <official_title>A Study Comparing Intermittent Androgen Depriving Therapy With Or Without Salvage High-Dose Intensity Modulation Radiotherapy (IG-IMRT)To Oligometastatic Pelvic Lymph Nodes In Biochemically-relapsing Prostate Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Direction Générale de l'Offre de Soins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of&#xD;
      disease, and treatment is focused on delaying progression rather than eliminating all tumor&#xD;
      burden. Local therapies, and specifically radiotherapy, have been directed at quality of life&#xD;
      endpoints and not at improving survival. However, advances in imaging and systemic therapy&#xD;
      have identified a population of 'oligometastatic' patients who have a lower burden of&#xD;
      metastatic disease (usually ≤5 lesions), who may present an exception. This condition is&#xD;
      hypothesized to occupy the hinterland between incurable metastatic disease and locoregional&#xD;
      disease, where micrometastatic disease is assumed to exist and yet remain eradicable.&#xD;
      Oligometastases can be detected using standard imaging but the sensitivity of these exams is&#xD;
      very low for patients with a PSA below 10 ng/ml. In France, FCH PET imaging is now routinely&#xD;
      available in a large majority of cancer centres. More recently, PSMA PET imaging has been&#xD;
      developed.&#xD;
&#xD;
      Since most oligometastases are now discovered at a time when conventional imaging is unable&#xD;
      to detect metastases, we must rely on the literature regarding purely biochemically-relapsing&#xD;
      prostate cancer patients. Three strategies have been explored: (i) observation until symptoms&#xD;
      develop, (ii) early intermittent Androgen Deprivation Therapy (IADT) and (iii) continuous&#xD;
      Androgen Deprivation Therapy (ADT). Recent data suggest that, of the three strategies, early&#xD;
      intermittent ADT was superior in term of overall survival to observation in controlling&#xD;
      metastatic prostate cancer, and this effect was similar in the biochemically-relapsing&#xD;
      prostate cancer patient population.&#xD;
&#xD;
      This phase III study will explore the role of salvage pelvic IG-IMRT combined with&#xD;
      intermittent ADT (IADT) in pelvic oligometastatic patients in prolonging the first&#xD;
      failure-free interval between the first and the second intermittent ADT courses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening procedures will be performed up to three months before starting IADT. After&#xD;
      obtaining informed consent, patients will be randomly allocated to one of two groups:&#xD;
&#xD;
      Experimental group: IADT + IG-IMRT Control group: IADT&#xD;
&#xD;
      In both study arms, the first injection of IADT will be administered in hospital on the day&#xD;
      of randomization. The overall duration of IADT will be six months.&#xD;
&#xD;
      In the experimental group, patients will receive radiotherapy three months after the first&#xD;
      injection of IADT.&#xD;
&#xD;
      The overall duration of radiotherapy will be three months.&#xD;
&#xD;
      The overall duration of IADT will be six months. It will be administered three months, +/- 15&#xD;
      days prior to the first day of radiotherapy. At the completion of the six-month treatment&#xD;
      period, a non-treatment interval will start if :&#xD;
&#xD;
      there is no evidence of clinical disease progression and the PSA level is ≤ 4.00 ng/ml If the&#xD;
      PSA subsequently rises above 0.20 ng/ml and is confirmed by a second measurement at least&#xD;
      three weeks later, PET/CT imaging will be repeated every 6 months until a clinical failure is&#xD;
      detected or until the PSA rises above 4.00 ng/ml.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>phase 3 study, randomised, open</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>90 months</time_frame>
    <description>PSA or CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>90 months</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to castration-resistance</measure>
    <time_frame>90 months</time_frame>
    <description>serum testosterone mesure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity to IADT and radiation</measure>
    <time_frame>90 months</time_frame>
    <description>evaluation with NCI-CTC AE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life during treatment</measure>
    <time_frame>90 months</time_frame>
    <description>questionnaire PR25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life during treatment</measure>
    <time_frame>90 months</time_frame>
    <description>questionnaire EQ-5D-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life during treatment</measure>
    <time_frame>90 months</time_frame>
    <description>questionnaire EORTC QLQ-C30 v3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>site of tumor progression</measure>
    <time_frame>90 months</time_frame>
    <description>FCH or PSMA PET at biochemical relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Oligometastasis</condition>
  <arm_group>
    <arm_group_label>IADT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one injection of IADT. The overall duration of IADT will be six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IADT+ radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of IADT. The overall duration of IADT will be six months. Irradiation three months after injection of IADT. The overall duration of radiotherapy will be three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IADT</intervention_name>
    <description>Patient will receive one injection of IADT at randomization</description>
    <arm_group_label>IADT</arm_group_label>
    <other_name>LH-RH (Luteinizing Hormone Releasing Hormone) agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>IADT + radiotherapy</intervention_name>
    <description>Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT</description>
    <arm_group_label>IADT+ radiotherapy</arm_group_label>
    <other_name>IG-IMRT</other_name>
    <other_name>LH-RH (Luteinizing Hormone Releasing Hormone) agonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-proven prostate adenocarcinoma&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Performance Status 0-1&#xD;
&#xD;
          -  Prior radical prostate treatment (surgery and/or radiotherapy)&#xD;
&#xD;
          -  ≤ 5 metastatic pelvic lymph nodes detected by FCH-PET or PSMA-PET&#xD;
&#xD;
          -  Upper limit of metastatic lymph nodes: aortic bifurcation&#xD;
&#xD;
          -  If ADT has been previously administered to the patient, at least 12 months must have&#xD;
             elapsed between the predicted duration of the last injection and inclusion of the&#xD;
             patient in the study. For this category of patients, serum testosterone must be higher&#xD;
             than 6 nmol/L (50 ng/L) prior to inclusion&#xD;
&#xD;
          -  Biochemical relapse (according to the European Association of Urology guidelines) is&#xD;
             defined by :&#xD;
&#xD;
        Following radical prostatectomy (RP), biochemical recurrence (BCR) is defined by two&#xD;
        consecutive rising PSA values &gt; 0.20 ng/ml After primary radiation therapy (RT), the&#xD;
        Radiation Therapy Oncology Group (RTOG) and American Society for Radiation Oncology Phoenix&#xD;
        Consensus Conference definition of PSA failure is any PSA increase &gt; 2.00 ng/ml higher than&#xD;
        the PSA nadir value, regardless of the serum concentration of the nadir.&#xD;
&#xD;
          -  Having given written informed consent prior to any procedure related to the study.&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including all scheduled treatment, visits and examinations.&#xD;
&#xD;
          -  Patient has valid health insurance&#xD;
&#xD;
          -  Subjects who have partners of childbearing potential must be willing to use a method&#xD;
             of effective birth control during treatment and for 12 months following completion of&#xD;
             treatment with ADT or IG-IMRT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bone or visceral metastases&#xD;
&#xD;
          -  Para-aortic lymph node metastases (above the aortic bifurcation)&#xD;
&#xD;
          -  Presence of more than five metastatic lymph nodes&#xD;
&#xD;
          -  Evidence of local intra-prostatic relapse&#xD;
&#xD;
          -  Evidence of prostate bed relapse in a previously irradiated region. Prostate bed&#xD;
             relapses which have not been previously irradiated will not be excluded&#xD;
&#xD;
          -  Evidence of metastasis at initial diagnosis&#xD;
&#xD;
          -  Evidence of distant metastases beyond the pelvic lymph nodes&#xD;
&#xD;
          -  Previous irradiation of pelvic lymph nodes&#xD;
&#xD;
          -  Castration-resistant prostate cancer (CRPC) as defined by : a castrate serum&#xD;
             testosterone &lt; 6 nmol/L (50 ng/L)&#xD;
&#xD;
          -  Contraindications to pelvic irradiation (e.g. chronic inflammatory bowel disease)&#xD;
&#xD;
          -  Contraindications to ADT (known hypersensitivity to any of the study drugs or&#xD;
             excipients)&#xD;
&#xD;
          -  Severe uncontrolled hypertension defined as systolic BP ≥ 160 mmHg or diastolic BP ≥&#xD;
             95 mmHg). Patients with a history of hypertension are allowed provided blood pressure&#xD;
             is controlled by anti-hypertensive therapy&#xD;
&#xD;
          -  Other malignancy treated within the last 5 years (except non-melanoma skin cancer)&#xD;
&#xD;
          -  Patients with a biochemical relapse while on active treatment with LHRH-agonist,&#xD;
             LHRH-antagonist, anti-androgen, maximal androgen blockade, or oestrogen&#xD;
&#xD;
          -  Treatment during the past month with products known to influence PSA levels (such as&#xD;
             finasteride)&#xD;
&#xD;
          -  In case of previous prostate/prostate bed radiotherapy, PET-positive lymph nodes have&#xD;
             to be located outside the previous irradiation field with a maximum of 20 Gy to the&#xD;
             PET-positive lymph nodes region&#xD;
&#xD;
          -  Patients already included in another therapeutic trial with an experimental drug or&#xD;
             having been given an experimental drug within a period of 30 days&#xD;
&#xD;
          -  Disorder precluding understanding of trial information or informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>STEPHANE SUPIOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>STEPHANE SUPIOT, MD</last_name>
    <phone>02 40 67 99 00</phone>
    <phone_ext>+33</phone_ext>
    <email>stephane.supiot@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MARINE TIGREAT</last_name>
    <phone>0241352821</phone>
    <phone_ext>+33</phone_ext>
    <email>marine.tigreat@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LYSIAN CARTIER, MD</last_name>
      <email>l.cartier@isc84.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PAUL SARGOS, MD</last_name>
      <email>p.sargos@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALI HASBINI, MD</last_name>
      <email>alihasbini@oncologie-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Bourgogne</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BENJAMIN SCHIPMAN, MD</last_name>
      <email>benschipman@yahou.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GENEVIEVE LOOS, MD</last_name>
      <email>Genevieve.LOOS@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GILLES CREHANGE, MD</last_name>
      <email>GCrehange@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAVID PASQUIER, MD</last_name>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PASCAL POMMIER, MD</last_name>
      <email>pascal.pommier@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DAVID AZRIA, MD</last_name>
      <email>david.azria@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Azureen de Cancerologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PHILIPPE RONCHIN, MD</last_name>
      <email>ronchinp@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>STEPHANE SUPIOT, MD</last_name>
      <phone>02 40 67 99 13</phone>
      <phone_ext>+33</phone_ext>
      <email>Stephane.Supiot@ico.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>MARINE TIGREAT</last_name>
      <phone>02 40 67 98 78</phone>
      <phone_ext>+33</phone_ext>
      <email>marine.tigreat@ico.unicancer.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Privé du Confluent</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>XAVIER BUTHAUD, MD</last_name>
      <email>xavier.buthaud@groupeconfluent.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PHILIPPE BERGEROT, MD</last_name>
      <email>philippe.bergerot@mla.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICL Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NICOLAS MAGNE, MD</last_name>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Saint Yves</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ERIK MONPETIT, MD</last_name>
      <email>mylittle@centre-st-yves.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligometastatic pelvic lymph nod, IADT, radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

